Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952336263> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2952336263 endingPage "1637" @default.
- W2952336263 startingPage "1630" @default.
- W2952336263 abstract "Abstract Aim To compare the cost‐effectiveness of secukinumab vs adalimumab at 1 and 2 years of treatment in patients with ankylosing spondylitis (AS) by analyzing the cost per responder reported in randomized controlled trials (RCTs) from the Korean perspective. Method A systematic literature search was performed via PubMed for relevant RCTs for comparing the response rate in patients with AS. The response rates in anti‐tumor necrosis factor‐naive subjects were extracted from RCTs and cost per responder analyses were calculated in case of both with or without a loading dosage of secukinumab compared with adalimumab. Results The Assessment in AS International Working Group (ASAS) 20 and 40 response rates of secukinumab from the MEASURE 2 trial and those of adalimumab from the ATLAS trial were comparable. The cost per ASAS 20 responder was lower by 40% in secukinumab compared to adalimumab: USD9637 vs 16 129 at 52 weeks and USD20 051 vs 32 699 at 104 weeks for secukinumab (in maintenance dosing) vs adalimumab, respectively. The cost per ASAS 40 responder was also lower by 40% in secukinumab: USD12 179 vs 22 395 at 52 weeks and USD27 338 vs 41 655 at 104 weeks for secukinumab vs adalimumab, respectively. With a loading dosage of secukinumab at 52 and 104 weeks, secukinumab showed lower costs per responder by 25% compared to adalimumab. Conclusion The costs per responder associated with ASAS 20 and 40 response rates were consistently lower for secukinumab compared with adalimumab. The treatment with secukinumab for patients with AS could be a cost‐saving treatment option in South Korea." @default.
- W2952336263 created "2019-06-27" @default.
- W2952336263 creator A5000534262 @default.
- W2952336263 creator A5075307711 @default.
- W2952336263 creator A5079117039 @default.
- W2952336263 creator A5087445199 @default.
- W2952336263 date "2019-06-18" @default.
- W2952336263 modified "2023-10-18" @default.
- W2952336263 title "A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective" @default.
- W2952336263 cites W1990305566 @default.
- W2952336263 cites W2018410379 @default.
- W2952336263 cites W2086560514 @default.
- W2952336263 cites W2097209079 @default.
- W2952336263 cites W2101141197 @default.
- W2952336263 cites W2113411136 @default.
- W2952336263 cites W2130303906 @default.
- W2952336263 cites W2166444828 @default.
- W2952336263 cites W2278932593 @default.
- W2952336263 cites W2462554540 @default.
- W2952336263 cites W2496735567 @default.
- W2952336263 cites W2510779786 @default.
- W2952336263 cites W2522711963 @default.
- W2952336263 cites W2525873843 @default.
- W2952336263 cites W2572897530 @default.
- W2952336263 cites W2591276563 @default.
- W2952336263 cites W2617420449 @default.
- W2952336263 cites W2765403114 @default.
- W2952336263 cites W2776657901 @default.
- W2952336263 cites W2804943760 @default.
- W2952336263 cites W2898749318 @default.
- W2952336263 cites W2902437733 @default.
- W2952336263 cites W4210974969 @default.
- W2952336263 doi "https://doi.org/10.1111/1756-185x.13635" @default.
- W2952336263 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31215166" @default.
- W2952336263 hasPublicationYear "2019" @default.
- W2952336263 type Work @default.
- W2952336263 sameAs 2952336263 @default.
- W2952336263 citedByCount "5" @default.
- W2952336263 countsByYear W29523362632022 @default.
- W2952336263 countsByYear W29523362632023 @default.
- W2952336263 crossrefType "journal-article" @default.
- W2952336263 hasAuthorship W2952336263A5000534262 @default.
- W2952336263 hasAuthorship W2952336263A5075307711 @default.
- W2952336263 hasAuthorship W2952336263A5079117039 @default.
- W2952336263 hasAuthorship W2952336263A5087445199 @default.
- W2952336263 hasConcept C126322002 @default.
- W2952336263 hasConcept C168563851 @default.
- W2952336263 hasConcept C17991360 @default.
- W2952336263 hasConcept C2776260265 @default.
- W2952336263 hasConcept C2777402515 @default.
- W2952336263 hasConcept C2777575956 @default.
- W2952336263 hasConcept C2779786854 @default.
- W2952336263 hasConcept C2780132546 @default.
- W2952336263 hasConcept C71924100 @default.
- W2952336263 hasConceptScore W2952336263C126322002 @default.
- W2952336263 hasConceptScore W2952336263C168563851 @default.
- W2952336263 hasConceptScore W2952336263C17991360 @default.
- W2952336263 hasConceptScore W2952336263C2776260265 @default.
- W2952336263 hasConceptScore W2952336263C2777402515 @default.
- W2952336263 hasConceptScore W2952336263C2777575956 @default.
- W2952336263 hasConceptScore W2952336263C2779786854 @default.
- W2952336263 hasConceptScore W2952336263C2780132546 @default.
- W2952336263 hasConceptScore W2952336263C71924100 @default.
- W2952336263 hasIssue "9" @default.
- W2952336263 hasLocation W29523362631 @default.
- W2952336263 hasLocation W29523362632 @default.
- W2952336263 hasOpenAccess W2952336263 @default.
- W2952336263 hasPrimaryLocation W29523362631 @default.
- W2952336263 hasRelatedWork W2606290205 @default.
- W2952336263 hasRelatedWork W2765259856 @default.
- W2952336263 hasRelatedWork W2765262888 @default.
- W2952336263 hasRelatedWork W2765460113 @default.
- W2952336263 hasRelatedWork W2767102936 @default.
- W2952336263 hasRelatedWork W2905601990 @default.
- W2952336263 hasRelatedWork W2906115491 @default.
- W2952336263 hasRelatedWork W2952336263 @default.
- W2952336263 hasRelatedWork W2994755740 @default.
- W2952336263 hasRelatedWork W3047154669 @default.
- W2952336263 hasVolume "22" @default.
- W2952336263 isParatext "false" @default.
- W2952336263 isRetracted "false" @default.
- W2952336263 magId "2952336263" @default.
- W2952336263 workType "article" @default.